Ubs Asset Management Americas Inc Dyne Therapeutics, Inc. Transaction History
Ubs Asset Management Americas Inc
- $477 Billion
- Q2 2025
A detailed history of Ubs Asset Management Americas Inc transactions in Dyne Therapeutics, Inc. stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 293,644 shares of DYN stock, worth $3.71 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
293,644
Previous 157,791
86.1%
Holding current value
$3.71 Million
Previous $1.65 Million
69.39%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding DYN
# of Institutions
211Shares Held
122MCall Options Held
36.5KPut Options Held
74.3K-
Ra Capital Management, L.P. Boston, MA9.71MShares$123 Million2.02% of portfolio
-
Janus Henderson Group PLC London, X09.44MShares$119 Million0.05% of portfolio
-
Atlas Venture Life Science Advisors, LLC9.13MShares$115 Million19.12% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.65MShares$96.6 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.39MShares$93.2 Million0.01% of portfolio
About Dyne Therapeutics, Inc.
- Ticker DYN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 51,765,400
- Market Cap $653M
- Description
- Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and...